Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IAR-038
- Development stage
- Preclinical
- Lead developer
- Innovent Biologics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
IAR-038 is a **bispecific antibody** targeting both **CD28** (a T-cell-specific surface glycoprotein) and **PSMA** (prostate-specific membrane antigen)[1][5]. Developed by Innovent Biologics, IAR-038 functions as a **CD28 agonist** and **PSMA inhibitor**, designed to provide tumor-targeted immune activation for cancer therapy, especially in castration-resistant prostate cancer (CRPC)[1][5]. Its activity is highly dependent on CD3 and PSMA presence, and its tumor-killing effect is enhanced through combination with anti-PD1 antibodies. In preclinical studies, IAR-038 showed moderate in vitro activity, superior in vivo tumor killing, improved half-life, and a potentially widened therapeutic window, indicating greater safety and efficacy for cancer patients[5].
- Brand names
- IAR-038IAR038IAR 038
- Other names
- IAR-038IAR038IAR 038
02
Targets
CD28 (Cluster of Differentiation 28)
Beyond the preview
Go deeper on IAR-038.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IAR-038.